ISTH 2021 Congress Archives - Page 2 of 91

Abstract Number: PB0556

Randomized Clinical Trial of PK-guided Treatment of Desmopressin Combined with FVIII Concentrate versus Only FVIII Concentrate in Peri-operative Hemophilia A Patients: Final Results of the Little DAVID Study

L.G.R. Romano¹, L.M. Schütte¹, R.M. van Hest², K. Meijer³, B.A.P. Laros - van Gorkom⁴, F.C.J.I. Heubel-Moenen⁵, M.H.E. Driessens⁶, S. Polinder⁷, M.H. Cnossen⁸, F.W.G. Leebeek¹, R.A.A. Mathôt², M.J.H.A. Kruip¹, On behalf of the SYMPHONY Consortium
Abstract Number: PB0969

Rapid and Complete Clearance of HPA-1a Mismatched Platelets in a Human Model of Fetal and Neonatal Alloimmune Thrombocytopenia by a Hyperimmune Plasma Derived Polyclonal Anti HPA-1a Antibody

C. Geisen¹, E. Fleck¹, S.M.G. Schäfer², C. Walter², S. Braeuninger¹, K. Olsen³, Z. Bhagwagar⁴, A. Mortberg⁵, A. Wikman^5,6, M. Kjaer^7,8, J. Kjeldsen-Kragh^9,10, F. Behrens², E. Seifried¹, M. Köhm²
Abstract Number: PB0049

Rapid Detection of DOACs in DVT Patients Using a Single-use Microfluidic Chip under Whole Blood Flow

J.M. Rossi¹, K.A. Panckeri², A.C. Cuker², S.L. Diamond¹
Abstract Number: PB1035

Rapid Internalization and Nuclear Translocation of CCL5 and CXCL4 in Endothelial Cells

A. Dickhout¹, M.A. van Zandvoort¹, R.R Koenen¹
Abstract Number: PB0708

Rare Bleeding Disorders in Children. Towards Establishing a Local Registry

D. Florinskiy¹, D. Fedorova¹, A. Poletaev¹, E. Seregina¹, A. Pshonkin¹, P. Zharkov¹
Abstract Number: PO187

Rare Complications of DOAC Treatment

M. Hulikova¹, S. Hulik², J. Hulikova¹
Abstract Number: PB0037

Rat Model of Metabolic Disorders: Dynamics of Hemostasis and Endothelial Function Changes

T. Obergan¹, L. Lyapina¹, M. Grigorjeva¹, T. Shubina¹
Abstract Number: PB0609

Rationale and Design of the “International Registry on the Symptomatic Hemophilia A/B Carriers”

S. Pasca¹, R. Sidonio Jr.², E. Grandone³, E. Zanon¹, M. Othman⁴
Abstract Number: PB0564

Real World Data on Haemophilia A Patients Switching to rFVIIIFc Treatment in Greece. Interim Results from the Multicenter Observational Study TOOL

O. Katsarou¹, A. Kouramba¹, E. Nomikou², G. Kampelos², S. Vakalopoulou³, H. Moka³, M. Economou⁴, V. Gourtsa⁴, E. Michalopoulou⁵, H. Pergantou⁵
Abstract Number: PO164

Real World Experience Use of DOAC in APLS Patients

Y.Y. Yap¹, R.b. Ramli¹, J. Suriar², J. Sathar¹
Abstract Number: PB0637

Real World Experience with Emicizumab with Hemophilia A Treated in Private Practice in Mexico

M.T. Pompa Garza¹, A. Arias Aranda², R. Miranda Madrazo³, N. Padilla Duron⁴, C.S. Gómez González⁵
Abstract Number: PB0577

Real-world Annual Bleeding Rate in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non interventional, before-after Study with the French BERHLINGO Database (MOTHIF-II)

V. Horvais¹, N. Drillaud¹, M. Sigaud¹, M. Fouassier¹, C. Ternisien¹, Y. Repesse², B. Guillet³, S. Bayart³, P. Beurrier⁴, L. Ardillon⁵, Y. Gruel⁵, J.-B. Valentin⁵, S. Bauer⁶, B. Pan-Petesch⁷, V. Cussac⁸, J. Rose⁸, M. Pennetier¹, M. Trossaërt¹, BERHLINGO Group
Abstract Number: PB0452

Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in France: Findings from the CHESS II Study

A. Shaikh¹, T. Burke^1,2, C. Hawes³, G. Duport⁴, J. O'Hara^1,2, C. Camp³
Abstract Number: PB0487

Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Germany: Findings from the CHESS II Study

A. Shaikh¹, T. Burke^1,2, C. Hawes³, T. Becker⁴, S. Brandt⁴, J. O'Hara^1,2, C. Camp³
Abstract Number: PB0464

Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Italy: Findings from the CHESS II Study

A. Shaikh¹, T. Burke^1,2, C. Hawes³, A. Lupi⁴, J. O'Hara^1,2, C. Camp³
Abstract Number: PB0456

Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in Spain: Findings from the CHESS II Study

A. Shaikh¹, T. Burke^1,2, C. Hawes³, J. O'Hara^1,2, C. Camp³
Abstract Number: PB0479

Real-world Clinical and Patient-centric Outcomes in People with Haemophilia A in the United Kingdom: Findings from the CHESS II Study

A. Shaikh¹, T. Burke^1,2, C. Hawes³, W. McKeown⁴, D. Morgan⁴, J. O'Hara^1,2, C. Camp³
Abstract Number: PB1252

Real-world Data on the Use of Oral Anticoagulants for the Treatment of Venous Thromboembolism in Sweden: Oral Anticoagulant Use and Baseline Characteristics from the Venous Thromboembolism Treatment Study

A. Gottsäter¹, H. Pohjantähti-Maaroos², K. Bokenberger³, S. Graham⁴, A. Jenkins⁵, D. Lambrelli⁴, K. Mercaldi⁶, M. Raluy³, W. Ghanima⁷
Abstract Number: PB0099

Real-world Effectiveness of BAY 94-9027 to Treat Hemophilia A in the ATHNdataset

C. He¹, M. Chandler¹, M. Recht¹, J. Charlet², T. Moulton², P. Vashi²
Abstract Number: PB0537

Real-world Experience in Introducing Emicizumab Prophylaxis for Adults with Haemophilia A without Inhibitors

N. Larkin¹, E. Singleton¹, J. Benson¹, N. Boland¹, J. Cleary¹, S. Brady¹, D. Gorman¹, N. Flynn¹, F. Ryan¹, M. Mc Gowen¹, S. Roche¹, C. Bergin¹, B. Mary¹, K. Ryan¹, M. Lavin¹, J.S O Donnell¹, N. O Connell¹
Abstract Number: PB0677

Real-world Experience of Emicizumab Treatment Using Entire Vials Only

K. Fischer¹, A.A. Donners¹, R.T Urbanus¹, I.C. Kremer Hovinga¹, L.F. van Vulpen¹, P.R van der Valk¹, K.P. van Galen¹, N. Uitslager¹, R.E. Schutgens¹
Abstract Number: PB0645

Real-world Experience of rIX-FP Prophylaxis at Dosing Intervals of up to 14 Days in a Pediatric Patient with Hemophilia B during the COVID-19 Pandemic

B.L. Díaz Jordan¹, T. Cebanu², M.T. Álvarez Román²
Abstract Number: PB0550

Real-world Joint Bleeding Rates in Patients with Congenital Hemophilia and Inhibitors: Final Data from the FEIBA Global Outcome (FEIBA GO) Study

J. Windyga¹, C. Hermans², P.A. Holme³, C. Escuriola-Ettingshausen⁴, A.R. Cid⁵, K. Khair⁶, J. Oldenburg⁷, J. Botha⁸, N. Kemenyash⁸, M. Kokot-Kierepa⁸, C. Négrier⁹
Abstract Number: PB0463

Real-world Outcomes in People with Severe Hemophilia B Receiving FIX Prophylaxis across Europe: A CHESS II Analysis

T. Burke^1,2, S. Asghar¹, J. O'Hara^1,2, M. Chuang³, E. Sawyer³, N. Li³
Abstract Number: PB0551

Real-world Usage of rFIXFc in Sweden: A Report from the Swedish National Registry for Bleedings Disorders

A. Olsson¹, L. Myrin-Westesson¹, F. Baghaei¹, M. Holmström^2,3, E. Olsson², M. Magnusson^2,4,5, S. Ranta⁴, J. Astermark⁶, N. Gretenkort Andersson⁷, J. Thanner⁸, J. Szamosi⁸, K. Sennfält⁸
Abstract Number: OC 08.4

Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database

M.E. Mancuso¹, P. Chelle², E. Iserman³, T. Matthew³, A. Keepanasseril³, A. Edginton², A. Iorio^3,4, WAPPS-Hemo Investigators
Abstract Number: PB0501

Real-world Use of FVIII in People with Severe Hemophilia A without Inhibitor on Prophylaxis, Comparing Switched to rFVIII-Fc versus Non-switched Patients: A Multicentre, Retrospective, Non Interventional, before-after Study with the French Nationwide Claims Database (MOTHIF-II)

V. Horvais¹, N. Drillaud¹, M. Sigaud¹, M. Fouassier¹, C. Ternisien¹, Y. Repesse², B. Guillet³, S. Bayart³, P. Beurrier⁴, L. Ardillon⁵, Y. Gruel⁵, J.-B. Valentin⁵, S. Bauer⁶, B. Pan-Petesch⁷, V. Cussac⁸, J. Rose⁸, M. Pennetier¹, M. Trossaërt¹, BERHLINGO Group
Abstract Number: PB0946

Reclassification of von Willebrand Disease Classification and Effects of Vascular Dysfunction on von Willebrand Factor

H. Watson¹, Y.E. Ng²
Abstract Number: LPB0006

Recombinant Heparin: An Old Drug for the Modern World

B.E. Thacker¹, K. Thorne¹, C. Cartwright¹, J. Park¹, K. Glass¹, A. Chea¹, J.D. Esko², W. Jeske³, J.M. Walenga³, C.A. Glass¹
Abstract Number: PB0605

Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia

C. Pfrepper¹, K. Holstein², C. Koenigs³, C. Heller³, M. Krause⁴, M. Olivieri⁵, C. Bidlingmeier⁵, M. Sigl-Kraetzig⁶, J. Wendisch⁷, R. Klamroth⁸, S. Halimeh⁹, J. Oldenburg¹⁰, S. Horneff¹⁰, H. Richter¹¹, I. Wieland¹², A. Tiede¹²
Abstract Number: OC 45.4

Recovery of BAY 94-9027 [Jivi®] with One-stage Clotting and Chromogenic Assays: A Multicentre Study

P. Meijer¹, D. Adcock², M Hollestelle¹, R. Marlar³
Abstract Number: PB1199

Recurrence and Mortality Following First Venous Thromboembolism among Saudi Population: Single-centre Cohort Study

F. Aleidan¹, R. Almanea¹, N. Shalash¹, N. Alrajhi¹, A. Almoneef¹, S. Almousa¹, K. Abuelgasim¹
Abstract Number: PB1242

Recurrent Thromboembolic Risk in Paroxysmal Nocturnal Hemoglobinuria Patients not on Anticoagulation Treated with Terminal Complement Inhibition

G. Gerber¹, A. DeZern¹, S. Chaturvedi¹, R. Brodsky¹
Abstract Number: PO124

Recurrent Thrombosis and Antithrombin Deficiency

L. Stanciakova¹, P. Holly¹, J. Palova¹, M. Brunclikova¹, M. Dobrotova¹, T. Bolek², M. Samos², P. Kubisz¹, J. Stasko¹
Abstract Number: PB1273

Recurrent Thrombosis Rescued by Fondaparinux in High-risk Patients: Case Series and Review of Literature

M. Tanguay¹, C. Séguin²
Abstract Number: PB0582

Reducing the Time of HAL and pedHAL Assessment

I.A. Kuijlaars¹, J. van der Net², V. Bouskill³, P. Hilliard⁴, A. Juodyte⁵, K. Khair⁶, R.E. Schutgens¹, S.S. Trakymiene⁵, K. Fischer¹
Abstract Number: PB0115

Refining and Validating a Model of FXI Activation and Activity in Thrombin Generation and Blood Coagulation

H.H.S. Lakshmanan¹, A. Estonilo², C. Puy¹, T. J. Zheng¹, J. Maddala³, D. Gailani⁴, J. J. Shatzel¹, A. Gruber¹, P. L. Jurney², O. J.T. McCarty¹
Abstract Number: PB0444

Refractory Acquired Hemophilia A (Even More) Complicated with SARS-CoV-2 Infection

C. Gomez del Castillo Solano¹, M. Fernández Docampo¹, T. Lado Cives¹, M.T. Fernández Fernández¹, D. Martínez Señarís¹, A. Hevilla Carmona¹, M.F. López Fernández¹
Abstract Number: PB0824

Refractory Immune Thrombocytopenia (ITP): The Combination of Thrombopoietin Analogs and Immunosuppressants, Experience in a Single Spanish Center

I. Sánchez Bazán¹, S. Martín Téllez¹, F.J. López Jaime¹, M.I. Muñoz¹
Abstract Number: PO161

Refractory Thrombotic Thrombocytopenic Purpura – A Case Report

A. Aribandi¹, C. Ranjith¹, S. Sushma², T. Surapaneni²
Abstract Number: PB0711

Registry of Patients with Congenital Bleeding Disorders from a Single Centre: Clinical and Analytical Characteristics

A. Lorenzo Jambrina¹, A. Torres Tienza¹, M. Mosquera Tapia¹, S. Marcellini Antonio¹, A. García Mateo¹, J.A. Queizán Hernández¹
Abstract Number: OC 16.2

Regulation of Endothelial Cell Procoagulant Activity by TMEM16 Scramblases

A. Schmaier¹, S. Chen¹, K. Sack¹, R. Flaumenhaft¹, S. Parikh¹, S. Schulman¹
Abstract Number: OC 10.1

Regulation of P2Y₁₂ Receptor Expression and Activity by cAMP Mediated PKA Signalling in Human Platelets; A Novel Mode of Action of Anti-platelet Drugs?

J. Khalil¹, K. Naseem², S. Mundell¹
Abstract Number: PO134

Reinforcement of Platelets Activity in Patients with Acute Myeloid Leukemia (AML) and Concomitant COVID-19 Infection

Z. Stupakova¹, I. Dyagil¹, O. Karnabeda², H. Menzarar³
Abstract Number: PB0298

Relationship between von Willebrand Factor and Clinical Outcome in Patients with Severe COVID-19

F. Rivera-Buendia¹, L.E. Garcia-Chavez¹, E. Cortina-de la Rosa¹, F.A. Grimaldo-Gomez¹, G.A. Altamirano-Solorzano¹, V.M. Anguiano-Alvarez¹, M.O. Romero-Arroyo¹, R. Izaguirre-Avila¹
Abstract Number: OC 34.3

Remote History of Venous Thrombosis and the Risk of Venous Thrombosis beyond the Age of 70 Years

H. Wang¹, F.R Rosendaal¹, M. Cushman², A. van Hylckama Vlieg¹
Abstract Number: LPB0104

Resistance to Fibrinolysis in Critically Ill Patients with COVID-19 Can Be Overcome by N-acetylcysteine in vitro

D. Faille¹, M.-C. Bourrienne², J. Gay¹, B. Ho-Tin-Noé², S. Loyau², V. Andrieu¹, C. Achard¹, C. Cavalié¹, M. Jandrot-Perrus², C.V Denis³, S. Ruckly¹, J. Patrier¹, P.-H. Wicky¹, E. de Raucourt⁴, R. Sonneville¹, J.-F. Timsit¹, N. Ajzenberg¹
Abstract Number: PB0803

Resolution Rates of Provoked Deep Vein Thrombosis and Pulmonary Embolism in Pediatric Patients Managed at a Tertiary Care Center

M. Dhaliwal¹, A. Chan¹, M. Bhatt¹
Abstract Number: OC 13.2

Response to Treatment for Gastro-intestinal Bleeding in Patients Affected by von Willebrand Disease

E. Biguzzi¹, S.M. Siboni¹, S. Braham¹, M.T. Pagliari¹, F. Peyvandi²
Abstract Number: PB0662

Responses to Anxiety and Depression Items in People with Hemophilia who Tested a Patient Reported Outcome Measure: The coreHEM MH Study

E. Clearfield¹, H.-Y. Chang¹, T. Majid², M.W. Skinner³
Abstract Number: OC 18.1

Result of a Study on Inter-laboratory Variability in the Measurement of Emicizumab and the Interference of Emicizumab in a Variety of Coagulation Tests

P. Meijer¹, M. Hollestelle¹, M. de Maat^2,1
Abstract Number: PB0536

Results from the Eptacog Beta in the Treatment of Bleeding Episodes of all Severities in Pediatric Hemophilia A or B Patients with Inhibitors

G. Castaman¹, S.W. Pipe², M. Callaghan³, J. Ducore⁴, M. Escobar⁵, C. Hermans⁶, J. Mahlangu⁷, U. Nowak-Göttl⁸, J. Journeycake⁹, S. Meeks¹⁰, M. Recht¹¹, M. Wang¹², G. Young¹³, N. Chambron¹⁴, A. AL-Sabbagh¹⁵, D. Bonzo¹⁵, C. Macie¹⁶, I.S. Mitchell¹⁷, A. Shapiro¹⁸
Abstract Number: PB0796

Results of a Multinational Survey of Diagnosis, Practices and Expertise in the Management of Venous Thromboembolism (VTE) in Pediatric Patients with Sickle Cell Disease (SCD)

M. Betensky¹, R. Kumar², N.A. Goldenberg³
Abstract Number: LPB0138

Results of a Prospective, Observational, Multi-center Cohort Study of Venous Thromboembolism Outcomes in Thrombocytopenic Cancer Patients (TROVE Study)

B. Carney¹, T.-F. Wang², S. Ren³, G. George⁴, A. Al Homssi⁵, M. Gaddh⁶, G. Connolly⁷, V. Shah⁸, T. Bogue¹, A. Bartosic⁹, D. Neuberg³, L. Baumann Kreuziger¹⁰, J. Zwicker¹
Abstract Number: PB0928

Results of a Survey Regarding the Diagnosis, Investigation and Management of Unclassified Bleeding Disorders amongst United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) Members

W. Thomas¹, K. Downes¹, G. Evans², G. Gidley³, G. Lowe⁴, S. MacDonald¹, S. Obaji⁵, J. O'Donnell⁶, F. Pinto⁷, M. Desborough^8,9
Abstract Number: PB1238

Results of DOAC Dipstick Test in Outpatients with Venous Thromboembolic Disease Are Comparable to Plasma Levels of Direct Oral Inhibitors – An Efficient Assessment Tool

L. Papageorgiou^1,2, J. Harenberg³, S. Auge⁴, L. Tredler⁵, I. Elalamy^1,2, G. Gerotziafas^1,2
Abstract Number: PB0472

Results of Thrombin Generation Assay in Patients Treated with Emicizumab

B. Baran¹, E. Stefanska-Windyga¹, A. Buczma¹, E. Odnoczko¹, J. Windyga²
Abstract Number: PB1030

Resveratrol Prevents Platelet Activation by Inhibition of ROS Formation

N. Al Arawe¹, V. Shpakova², N. Rukoyatkina², S. Gambaryan^2,1
Abstract Number: PB1000

Reticulated Platelets in Healthy Volunteers. Relationships with Platelet Size Indexes and Platelet Activity

A. Mazurov¹, V. Bodrova¹, O. Shustova¹, S. Khaspekova¹
Abstract Number: PB0041

Reversal of Antithrombotic Effects of FXIa Inhibitor Milvexian (BMS-986177/JNJ-70033093) by Non-specific Agents in a Rabbit AV-shunt Model of Thrombosis

X. Wang¹, Q. Li¹, F. Du¹, J. Caruso¹, A. Nawrocki¹, M. Chintala¹
Abstract Number: PB0040

Reversal of Oral Anticoagulants: A Survey of Contemporary Practice Trends (ReACT)

H. Deng¹, R. DiDomenico^2,3, E. Nutescu^2,3
Abstract Number: PB1160

Reversible Factor Xa Inhibitors Specifically Inhibit, in Clot Growth, via the Intrinsic Tenase Complex: A Tool to Determine Specifically the In- and Extrinsic Contribution to Clot Growth

C. Kluft¹, S. Naji¹
Abstract Number: PB1311

Review of Intrapartum Management of ITP in Pregnancy in John Radcliffe Hospital

J. Dhanapal¹, S. Pavord¹
Abstract Number: PB0515

Reviewing HJHS as a Tool to Assess Outcome Measures in Patients with Haemophilia A in Australia

S. Parikh¹, C. George², S. McRae^3,1, T. Carter^2,1, A. Morris², C. Cramey⁴, K. McElroy⁵, H. Tran^6,1
Abstract Number: PB0335

Ring Trial for Quality Assurance of the Manual Tilt Tube Technique for Prothrombin Time and INR Determinations in WHO Calibration Laboratories

A. van den Besselaar¹, C. van Rijn¹, C. Cobbaert¹
Abstract Number: OC 12.4

Risk Factors for Gastrointestinal Bleeding in Patients with Gastrointestinal Cancer Using Edoxaban: Results from the Hokusai VTE Cancer Study

F.T. Bosch^1,2, F.I. Mulder^1,2, M.V. Huisman³, J. Zwicker⁴, M. Di Nisio⁵, M. Carrier⁶, A. Segers⁷, P. Verhamme⁸, S. Middeldorp⁹, J.I. Weitz¹⁰, M.A. Grosso¹¹, A. Duggal¹¹, H.R. Büller², T.-F. Wang⁶, D.A. Garcia¹², G.E. Raskob¹³, N. van Es²
Abstract Number: PB0104

Risk Factors for Non-variceal Hemorrhage in Patients with Chronic Liver Disease

P. Kesavan¹, A. Afzal¹, S. Luo^1,2, B. Gage¹, M. Schoen², K. Sanfilippo^1,2
Abstract Number: PB1130

Risk Factors for Reccurence of Catheter Related upper Extremity Deep Venous Thrombosis in Cancer Patients

R. Hakem¹, S. Soudet¹, M.A. Sevestre¹
Abstract Number: PB1052

Risk Factors for Recurrent Thrombosis and Cause of Death in Patients with Antiphospholipid Syndrome; A Swedish Cohort Study

N. Karandyszowska¹, H. Alagündüz¹, J. Oesman¹, M. Magnusson², E. Svenungsson³, A. Antovic³, M. Bruzelius¹
Abstract Number: PB1102

Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

D. Evstratov¹, P. Zharkov¹, N. Myakova¹
Abstract Number: PO120

Risk Factors for Venous Thromboembolism at the University College Hospital, Ibadan

W. Shokunbi¹, P. Ogundeji¹, O. Aworanti¹, C. Akunwata¹
Abstract Number: PB1129

Risk Factors of Catheter-related Thrombosis in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

A. Hoppe¹, J. Rupa-Matysek¹, B. Malecki¹, D. Dytfeld¹, L. Gil¹
Abstract Number: PB1204

Risk Factors of Venous Thromboembolism at Patients with Endoscopic Urological Interventions

D. Shorikova¹, E. Shorikov¹, P. Shorikov¹
Abstract Number: PB0330

Risk of Misdiagnosis for Patients Presenting the Closed Variants E1359K or V1360A in Exon 28 of VWF due to a Major Discordance on VWF Activity Results between the VWF:GpIbM and VWF:GpIbR Assays

F. Lassalle¹, E. Jeanpierre¹, C. Zawadzki¹, C. Pouymayou², S. Castet³, Y. Huguenin³, R. Marlu⁴, A. Voyer⁵, P. Chamouni⁶, J. Goudemand¹, S. Susen¹
Abstract Number: PB1113

Risk of Vascular Occlusive Events with PARPis in Cancer: A Systematic Review and Meta-analysis

H. Haguet¹, L. Ronvaux¹, J. Douxfils^1,2
Abstract Number: OC 23.2

Risk of Venous and Arterial Thromboembolic Events in Patients Receiving Targeted Anti-cancer Therapy – A Nationwide Cohort Study

F. Moik¹, C. Ay¹, E. Horváth-Puhó², I. Pabinger¹, F. Mulder³, N. van Es³, H.T. Sørensen²
Abstract Number: PB1095

Risk of Venous Thromboembolism and Major Bleeding in the Clinical Course of Osteosarcoma and Ewing Sarcoma Patients

M.A.M. Stals¹, F.HJ Kaptein¹, R.E Evenhuis², AJ Gelderblom³, M.V Huisman¹, DSA Karis², RWD Noten¹, SC Cannegieter^1,4, HH Versteeg¹, MAJ van de Sande², FA Klok¹
Abstract Number: OC 76.1

Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis – RIDTS Study

W. Ageno¹, L. Bertù¹, E. Bucherini², G. Camporese³, F. Dentali¹, M. Iotti⁴, G. Lessiani⁵, R. Parisi⁶, P. Prandoni⁷, M. Sartori⁸, A. Visonà⁹, G. Palareti⁷, RIDTS study group
Abstract Number: PB1062

Rivaroxaban versus Vitamin K Antagonist for the Secondary Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: A Systematic Review and Meta-analysis

R.D. Agustin¹, D.L. Villanueva¹, E. Alajar¹, M.T. Abola¹
Abstract Number: PB0219

Role of Endothelium Activation Biomarkers in Prediction COVID-19 Related Intra-hospital Mortality

M. Marchetti¹, P. Gomez-Rosas^2,1, L. Russo¹, E. Sanga¹, S. Gamba¹, C. Verzeroli¹, F. Restuccia¹, F. Schieppati¹, E. Bonanomi¹, M. Rizzi¹, S. Fagiuoli¹, A. D'Alessio³, L. Lorini¹, A. Falanga^1,4
Abstract Number: PB0305

Role of Hematological Parameters in Stratification of Covid-19 Disease Severity

S. Taj¹, A. Kashif¹, S. Arzinda Fatima¹, S. Imran¹, A. Lone¹, Q. Ahmed¹
Abstract Number: PB1150

Role of Individual Venous Symptoms and Signs at Baseline in Predicting Future Development of Post-thrombotic Syndrome: Sub-analysis of the ATTRACT Trial

F. Rinfret^1,2, C.-S. Gu³, S. Vedantham⁴, S. Kahn^2,1
Abstract Number: PB1159

Role of Inherited Thrombophilia in the Occurrence of Arterial Thrombosis after Venous Thromboembolism

A. Ciavarella^1,2, M. Abbattista¹, F. Gianniello¹, M. Capecchi^1,2, A. Artoni¹, I. Martinelli¹, F. Peyvandi^1,3
Abstract Number: LPB0097

Role of Low-dose Aspirin on the Release of Circulating Microvesicles in Patients at Cardiovascular Risk with and without Type 2 Diabetes

P. Simeone¹, R. Liani¹, R. Tripaldi¹, S. Ciotti¹, P. Lanuti¹, M. Marchisio¹, S. Miscia¹, F. Santilli¹
Abstract Number: PB0986

Role of Platelet GARP in TGFβ Activation

J. Bodart¹, C. Dufeys¹, Y. Senis², Z. Nagy³, L. Bertrand¹, C. Beauloye^1,4, S. Lucas⁵, S. Horman¹
Abstract Number: PB0982

Role of Platelet HIF-2 Alpha to Indorse Thrombogenicity through Synthesis of PAI-1 during Hypoxia

R.L. Mallick¹, S.N. Chaurasia², D. Dash², P. Mallick³
Abstract Number: PB0981

Role of Platelet’s Heme Oxygenase-1 in Obese Patients with and without Type 2 Diabetes Mellitus

R. Liani¹, P.G. Simeone¹, R. Tripaldi¹, S. Ciotti¹, P. Lanuti¹, G. Bologna¹, A. Boccatonda¹, D. D'Ardes¹, V. Luca², F. Santilli¹
Abstract Number: OC 02.4

Role of Shear Stress and tPA Concentration in the Fibrinolytic Potential of Thrombi

C. Whyte¹, A. Mostefai¹, K.M Baeten¹, A.J Lucking², D.E Newby², N.A Booth¹, N.J Mutch¹
Abstract Number: PB0865

Role of Soluble C5b-9 (sC5b-9) in Dosing Adjustments of Anti-complement Therapy during Pregnancy in a Patient with History of Atypical Hemolytic Uremic Syndrome (aHUS)

C. Dos Santos¹, G. Greloni², M.F. Alberto³, A. Sánchez-Luceros³
Abstract Number: LPB0018

Role of the “Mobile Loop” (Residues 142-150) in the Intrinsic Instability of TAFIa

H. Marier¹, M. Boffa¹
Abstract Number: OC 42.1

Role of the Coagulation Factor XIII Binding Site on Crosslinking of Fibrinogen αC (233 – 425)

F.D. Ablan¹, M. Hindi¹, M. Maurer¹
Abstract Number: PB0022

Role of the Interaction between Thrombophilia and Other Risk Factors in the Occurring of Ischemic Stroke in Young Patients: Algerian Restrospective Study about 75 Cases

M. El Horri¹, I. Khachaa¹, A. Chikh Khelifa¹, A. Berrah¹, M. Chekkal², F. Bemmoussat¹, L. Benmahdi¹, S.E. Belakehal¹
Abstract Number: LPB0023

Role of Tissue Factor in Delayed Bone Repair Induced by Diabetic State in Mice

K. Tatsumi^1,2, H. Ehara², Y. Takafuji², N. Kawao², M. Ishida², K. Okada², N. Mackman³, M. Shima¹, H. Kaji²
Abstract Number: PB1107

Role of Tissue Factor in the Procoagulant Shift of Endothelial Cells upon Exposure to Cancer Cell-derived Microparticles

R. Djedidi-Amrane^1,2, P. Vandreden², G. Gerotziafas^1,3,4
Abstract Number: PB0233

Rotational Thromboelastometry (ROTEM) Profiling of COVID–19 Patients

M. Mitrovic^1,2, N. Sabljic¹, Z. Svetkovic^3,2, N. Pantic¹, Z. Bukumiric⁴, N. Savic⁵, B. Milenkovic^6,2, M. Virijevic^1,2, Z. Pravdic¹, N. Suvajdzic^1,2, J. Fareed⁷, D. Antic^1,2
Abstract Number: PB0706

ROTEM in Combination with Bleeding History – Can it Serve as a Screening Test for Factor XIII Deficiency in Patients with Suspected Bleeding Disorder?

T. Geevar¹, R.G. Dave¹, T. David V¹, G. K C¹, R. Vijayan¹, A. Samuel¹, S. Singh¹, J. John Mammen¹, S. Chandran Nair¹
Abstract Number: LPB0040

rs2431697 of miR-146a Regulates NETosis Determining the Thickness of the Carotid Intima-media in Patients with Rheumatoid Arthritis

L. Reguilón Gallego¹, A.M. del los Reyes-García¹, S. Águila¹, M.P. Fernández-Pérez¹, N. García Barberá¹, L. Zapata-Martínez¹, I. Ruiz Lorente¹, M.C. Ábalos-Aguilera², E. Saiz³, M.F. Pina³, M.T. Herranz⁴, A. Barceló⁵, I. Hervés⁵, V. Vicente¹, C. López-Pedrera², C. Martínez¹, R. González-Conejero¹
Abstract Number: PB0439

Rutin Succinate Acts as an Anticoagulant and Inhibits Snake Venom Metalloproteinases in an Acute Thrombo-hemorrhagic Disorder Model

A.T.A. Sachetto¹, M.L. Santoro¹